Dr. Bruce Murphy
Assoc Prof. in Biomechanical Engineering, Mechanical, Manuf & Biomedical Eng
Biography
Dr. Bruce Murphy is an Associate Professor in the Department of Mechanical, Manufacturing and Biomedical Engineering, Deputy Director of the Trinity Centre for Biomedical Engineering, and Principal Investigator (PI) in the Trinity Centre for Biomedical Engineering and the Advanced Materials and Bioengineering Research (AMBER) Centre at Trinity College Dublin (TCD).
He runs one of the most successful medical device design incubator labs in the World. To date his lab has spun-out 4 TCD spin-outs: Croívalve, Selio Medical, Proverum and One Projects. The spinouts from his lab have raised over €100M in capital, employ over 100 full time equivalents, and have two devices in clinical trials.
Current projects in his lab include: MitrAdapt " a new percutaneous solution for treating patients with mitral regurgitation, PLIO " a new laparoscopic solution to reduce the leakage rates of anastomosis in the GI tract, IndexiTap " a collaboration with TCD"s Academic Unit of Neurology and Beaumont Hospital to understand if enhanced measurement of patient dexterity can better track symptoms of Motor Neuron Disease.
His lab is not only involved in translational Biomedical Engineering, he has published in many top journals in Biomedical Engineering. Including the top journal in the field, Nature Biomedical Engineering (IF >25). He is open to collaboration with artists and other professionals if they would like to explore or link aspects of medical device design or biomedical engineering to their work.
Publications and Further Research Outputs
Peer-Reviewed Publications
A. Glynn, A. Consoli, B. Murphy, R. McCarthy, C. Lally, Establishing an in-vitro system to investigate the influence of thrombus composition on the Shape of M1- Middle cerebral artery occlusion and the optimum thrombectomy strategy, ESOC2023, European Stroke Organisation Conference, May 24-26th, Munich, Germany,, 2023
A. Glynn, S. Johnson, B. Murphy, C. Lally, R. McCarthy, Investigation of the influence of composition, size and cerebral pressure on thrombus migration and deformation in an in vitro model, 28th Bioengineering in Ireland, January 27-28th, 2023., Kildare, Oral Presentation, 2023
A. Glynn, A. Consoli, B.P. Murphy, R McCarthy, C Lally, An In vitro assessment of emboli trajectories within a patient specific model: investigation into the influence of thrombus size, mechanical properties, and cerebral blood pressure, 2023 Summer Biomechanics, Bioengineering and bio transport conference, Vail Colorado, 4th - 8th June 2023, 2023
C. D. Hayden, B. P. Murphy, D. Gilsenan, B. Nasseroleslami, O. Hardiman, D. Murray, Clinical Validation of a Novel Device for Objective Measurement of Hand Dexterity, 34th International Symposium on ALS/MND, Basel, 2023, 2023
Hayden C.D., Murray D., Geraghty D, Meldrum D., Hardiman O., Murphy B.P., Design and Validation of a Novel Hand-Worn Sensor for Assessment of Dexterity in Neurological Conditions, Journal of Medical Devices, Transactions of the ASME, 17, (4), 2023, p045002
C.D. Hayden, D Murray, D Meldrum, D Geraghty, O Hardiman, B.P. Murphy, Development of a Novel Hand Worn Sensor For Objective Assessment of hand dexterity in Neurodegenerative Conditions, 2023 Summer Biomechanics, Bioengineering, and Biotransport Conference, Vail Colorado, 4th- 8th June, 2023, 2023
C. D. Hayden, B. P. Murphy, O. Hardiman and D. Murray, Traditional respiratory measurement and the current state of the field, European Network to Cure ALS Symposium, Barcelona, 2023, 2023
C. D. Hayden, D. Murray, D. Geraghty, D. Meldrum, O. Hardiman, and B. P. Murphy, Development of a Novel Dexterity Device for Assessment of Neurological Conditions,", Proceedings of the 28th Annual Conference of the Section of Bioengineering of the Royal Academy of Medicine in Ireland., Carlow, Ireland, 2023, 2023
C. D. Hayden, B. P. Murphy, O. Hardiman, D. Gilsenan and D. Murray, Traditional Methods of Quantifying Upper Limb Function in ALS and the Need for Objective Solutions, 33rd International Symposium on ALS/MND, Virtual, 2022, 2022
Alix Whelan, E. O'Connor, B. Hughes, M. Hensey, MB, B.P. Murphy, Mitral valve edge-to-edge repair: The importance of a `good bite", 2022 PCR London Valves, London, Nov 2022, 2022
D. Nolan, A. Glynn, S. Porter, x S. Johnson, R. McCarthy, B. Murphy, C. Lally, Understanding the influence of arterial stiffness in acute ischemic stroke, 27th Bioengineering in Ireland, May 20-21st, 2022, Galway, Oral Presentation, 2022
C. D. Hayden and B. P. Murphy and O. Hardiman and D. Murray, Measurement of upper limb function in ALS: a structured review of current methods and future directions, Journal of Neurology, 2022
Whelan, A., Williams, E., Fitzpatrick, E., Murphy, B.P., Gunning, P.S., O'Reilly, D., Lally, C., Collagen fibre-mediated mechanical damage increases calcification of bovine pericardium for use in bioprosthetic heart valves, Acta Biomaterialia, 128, 2021, p384-392
Greg Campion, Kylie Hershberger, Alix Whelan, Jack Conroy, Caitr ona Lally & Bruce P. Murphy, A Biomechanical and Microstructural Analysis of Bovine and Porcine Pericardium for Use in Bioprosthetic Heart Valves, Structural Heart, 5, (5), 2021, p486 - 496
C. D. Hayden, B. P. Murphy, D. Meldrum, O. Hardiman, and D. Murray, Measurement of Upper Limb Function in ALS: Current Methods and Future Directions, 32nd International Symposium on ALS/MND, Virtual, 2021, 2021
Alix Whelan, Elizabeth Williams, David Nolan, Bruce Murphy, Paul Gunning, David O'Reilly, Caitríona Lally, Bovine pericardium of high fibre dispersion has high fatigue life and increased collagen content; potentially an untapped source of heart valve leaflet tissue, Annals of Biomedical Engineering, 49, (3), 2021, p1022 - 1032
D. Nolan, A. Glynn, S. Porter, S. Johnson, R. McCarthy, B. Murphy, C. Lally, Using histological analysis to explore the variation in composition and stiffness of cerebral arterial tissue, 11th European Solid Mechanics Conference, July 4-8th, 2021, Oral Presentation, 2021
C. D. Hayden, D. Murray, D. Meldrum, O. Hardiman, and B. P. Murphy,, Development of Novel Dexterity Device for ALS Patients, Proceedings of the 26th Annual Conference of the Section of Bioengineering of the Royal Academy of Medicine in Ireland., Carlow, Ireland, 2020, 2020
C. D. Hayden, B. P. Murphy, D. Meldrum, O. Hardiman, and D. Murray, Development of Novel Dexterity Sensor in Amyotrophic Lateral Sclerosis, 31st International Symposium on ALS/MND, Virtual, 2020, 2020
Tatiane Eufrásio-da-Silva, Eduardo Ruiz-Hernandez, Joanne O'Dwyer, Dolores Picazo-Frutos, Garry P Duffy, Bruce P Murphy, Enhancing medial layer recellularization of tissue-engineered blood vessels using radial microchannels, Regenerative medicine, 14, (11), 2019, p1013 - 1028
Curley, C.J. and Dolan, E.B. and Otten, M. and Hinderer, S. and Duffy, G.P. and Murphy, B.P., An injectable alginate/extra cellular matrix (ECM) hydrogel towards acellular treatment of heart failure, Drug Delivery and Translational Research, 9, (1), 2019
Alix Whelan, Duffy J., Gaul R.T., O'Reilly D., Nolan D.R., Gunning P., Lally C., Murphy B.P., Collagen fibre orientation and dispersion govern ultimate tensile strength, stiffness and the fatigue performance of bovine pericardium, Journal of the Mechanical Behavior of Biomedical Materials, 90, 2019, p54 - 60
Dolan, E.B. and Hofmann, B. and de Vaal, M.H. and Bellavia, G. and Straino, S. and Kovarova, L. and Pravda, M. and Velebny, V. and Daro, D. and Braun, N. and Monahan, D.S. and Levey, R.E. and O'Neill, H. and Hinderer, S. and Greensmith, R. and Monaghan, M.G. and Schenke-Layland, K. and Dockery, P. and Murphy, B.P. and Kelly, H.M. and Wildhirt, S. and Duffy, G.P., A bioresorbable biomaterial carrier and passive stabilization device to improve heart function post-myocardial infarction, Materials Science and Engineering C, 103, (109751), 2019
Whyte, W. and Roche, E.T. and Varela, C.E. and Mendez, K. and Islam, S. and O'Neill, H. and Weafer, F. and Shirazi, R.N. and Weaver, J.C. and Vasilyev, N.V. and McHugh, P.E. and Murphy, B. and Duffy, G.P. and Walsh, C.J. and Mooney, D.J., Sustained release of targeted cardiac therapy with a replenishable implanted epicardial reservoir /692/4019/2773 /639/301/54/152 /14/5 /14/35 /14/63 /59/5 /96/106 /96/100 /96/34 article, Nature Biomedical Engineering, 2, (6), 2018, p416-428
Dolan, E.B. and Kovarova, L. and O'Neill, H. and Pravda, M. and Sulakova, R. and Scigalkova, I. and Velebny, V. and Daro, D. and Braun, N. and Cooney, G.M. and Bellavia, G. and Straino, S. and Cavanagh, B.L. and Flanagan, A. and Kelly, H.M. and Duffy, G.P. and Murphy, B.P., Advanced Material Catheter (AMCath), a minimally invasive endocardial catheter for the delivery of fast-gelling covalently cross-linked hyaluronic acid hydrogels, Journal of Biomaterials Applications, 33, (5), 2018, p681-692
Dolan, E.B. and Gunning, G.M. and Davis, T.A. and Cooney, G. and Eufrasio, T. and Murphy, B.P., The development and mechanical characterisation of a novel reinforced venous conduit that mimics the mechanical properties of an arterial wall, Journal of the Mechanical Behavior of Biomedical Materials, 71, 2017, p23-31
Bruce Murphy , Travis Davis, Sam Coffey, Corinna Welker, Deirdre Moroney, Jack Halpin., Design Changes Can Explain The Trends Of Reported Adverse Events Associated With Balloon Expandable And Self-expandable Transcatheter Aortic Valves, Heart Valve Society 2017 Annual Scientific Meeting, Grimaldi Forum " Monte Carlo, Monaco, March 2017, 2017
Jim Crowley, Michael Burke, Bruce Murphy, ClipValve: Pre-clinical results of a new mitral valve replacement system, PCR London Valves 2017, London, 2017
Curley, C.J. and Dolan, E.B. and Cavanagh, B. and O'Sullivan, J. and Duffy, G.P. and Murphy, B.P., An in vitro investigation to assess procedure parameters for injecting therapeutic hydrogels into the myocardium, Journal of Biomedical Materials Research - Part B Applied Biomaterials, 105, (8), 2017, p2618-2629
O'Neill, H.S., Gallagher, L.B., O'Sullivan, J., Whyte, W., Curley, C., Dolan, E., Hameed, A., O'Dwyer, J., Payne, C., O'Reilly, D., Ruiz-Hernandez, E., Roche, E.T., O'Brien, F.J., Cryan, S.A., Kelly, H., Murphy, B., Duffy, G.P., Biomaterial-Enhanced Cell and Drug Delivery: Lessons Learned in the Cardiac Field and Future Perspectives, Advanced Materials, 2016, p5648-5661-
Curley C. J., Dolan E. B., Hinderer S., Duffy G. P., and Murphy B. P., A new injectable alginate based hydrogel for acellular cardiac repair, The 22rd Annual Conference of the Section of Bioengineering of the Royal Academy of Medicine in Ireland 2016, Galway, Ireland, 2016
van Elk, M., Murphy, B.P., Eufrásio-da-Silva, T., (...), Duffy, G.P., Ruiz-Hernández, E., Nanomedicines for advanced cancer treatments: Transitioning towards responsive systems, International Journal of Pharmaceutics, 515, (1-2), 2016, p132-164
Gunning, G.M., Murphy, B.P., The effects of decellularization and cross-linking techniques on the fatigue life and calcification of mitral valve chordae tendineae, Journal of the Mechanical Behavior of Biomedical Materials, 57, 2016, p321-333
Gunning, G.M., Murphy, B.P., Characterisation of the fatigue life, dynamic creep and modes of damage accumulation within mitral valve chordae tendineae, Acta Biomaterialia, 24, 2015, p193-200
Curley C. J., Duffy G. P., and Murphy B. P., The effect of needle design on intramyocardial hydrogel retention in a thick decellularized matrix, The 21st Annual Conference of the Section of Bioengineering of the Royal Academy of Medicine in Ireland 2015, Kildare, Ireland, 2015
Curley C. J., Dolan E. B., Hinderer S., Duffy G. P., and Murphy B. P., Optimisation of hydrogel injection for regeneration of myocardial infarction, TERMIS World Congress 2015: Boston, MA, USA, 2015
Curley C. J., Duffy G. P., and Murphy B. P., Determination of optimal delivery parameters for intramyocardial injection of therapeutic loaded hydrogels, Proceedings of the 7th World Congress of Biomechanics 201 4, Boston, MA, USA, 2015
Sheridan, W.S., Ryan, A.J., Duffy, G.P., O"Brien, F.J., Murphy, B.P., An experimental investigation of the effect of mechanical and biochemical stimuli on cell migration within a decellularized vascular construct, Annals of Biomedical Engineering, 42, (10), 2014, p2029-2038
Sheridan, W.S., Ryan, A.J., Duffy, G.P., O'Brien, F.J., Murphy, B.P. , An Experimental Investigation of the Effect of Mechanical and Biochemical Stimuli on Cell Migration Within a Decellularized Vascular Construct, Annals of Biomedical Engineering, 2014
Michael Burke, Bruce Murphy, Dermot Geraghty, Measurement of Sub-Bandage Pressure During Venous Compression Therapy Using Flexible Force Sensors, IEEE Sensors, Valencia, Spain, November 2-5, 2014, pp1623 - 1626
Sheridan, W.S., Grant, O.B., Duffy, G.P., Murphy, B.P., The application of a thermoresponsive chitosan/β-GP gel to enhance cell repopulation of decellularized vascular scaffolds, Journal of Biomedical Materials Research - Part B Applied Biomaterials, 2014
Alan A. Hopkins,, William S. Sheridan, Faisal Sharif, Bruce P. Murphy, The effect of a thermal renal denervation cycle on the mechanical properties of the arterial wall, Journal of Biomechanics, In Press, 2014
Curley C. J., Duffy G. P., and Murphy B. P., Determination of optimal delivery parameters for intramyocardial injection of therapeutic loaded hydrogels, The 20st Annual Conference of the Section of Bioengineering of the Royal Academy of Medicine in Ireland 2014, Dublin, Ireland, 2014
Gillian M Gunning, Bruce P Murphy, Determination of the tensile mechanical properties of the segmented mitral valve annulus, Journal of Biomechanics, 47, (2), 2014, p334-340
Murphy BP, Breen LT, The Design of an Improved Force Focused Angioplasty Catheter, Journal of Medical Devices, 8, (1), 2014, p1 - 5
Sheridan, WS, Duffy, GP, Murphy, BP., Optimal Parameters for Freeze-drying Decellularized Arterial Scaffolds, The 19th Annual Conference of the Section of Bioengineering of the Royal Academy of Medicine in Ireland 2013, Meath, Ireland, 2013
Gunning, G.M., Sheridan, W.S., Murphy, B.P., The chink in the armor of the mitral valve annulus: the irregular distribution of mechanical properties, ASME SBC 2013, ASME 2013 Summer Bioengineering Conference, SBC 2013, Sunriver; United States, 26-29 June, 2013, pp1A-
Sheridan, W.S., Grant, O., Lopez-Noriega, A., Duffy, G.P., Murphy, B.P., Towards a clinically applicable tissue engineered vascular graft, ASME , SBC 2013, 2013 Summer Bioengineering Conference, United States;, 26-29 June, 2013, pp1 A-
Sheridan, WS, Duffy, GP, Murphy, BP, Optimum Parameters for Freeze-Drying Decellularized Arterial Scaffolds, TISSUE ENGINEERING PART C-METHODS, 19, (12), 2013, p981-990
Coghlan, KM, Breen, LT, Martin, Z, O'Neill, S, Madhaven, P, Moore, D, Murphy, BP, An Experimental Study to Determine the Optimal Access Route for Renal Artery Interventions, EUROPEAN JOURNAL OF VASCULAR AND ENDOVASCULAR SURGERY, 46, (2), 2013, p236-241
Curley C. J., Duffy G. P., and Murphy B. P., Optimisation of Cell Delivery Parameters into the Heart via Intramyocardial Injection, The 19th Annual Conference of the Section of Bioengineering of the Royal Academy of Medicine in Ireland 2013, Meath, Ireland, 2013
Keady, F, Murphy, BP, Investigating the feasibility of using a grit blasting process to coat nitinol stents with hydroxyapatite, JOURNAL OF MATERIALS SCIENCE-MATERIALS IN MEDICINE, 24, (1), 2013, p97-103
W.S. Sheridan, G.P. Duffy, B.P. Murphy, Mechanical characterisation of a customised decellularized scaffold for vascular tissue engineering, Journal of the Mechanical Behavior of Biomedical Materials, 8, 2012, p58 - 70
Sheridan, WS, Duffy, GP, Murphy, BP., Optimum Mechanical Properties and Cell Repopulation Techniques of a Decellularized Vascular Scaffold, The 18th Annual Conference of the Section of Bioengineering of the Royal Academy of Medicine in Ireland 2012, Belfast, Ireland, 2012
WS Sheridan, GP Duffy, BP Murphy, Injection Techniques for Bulk Cell Seeding Decellularized Vascular Scaffolds, International Journal of Nano and Biomaterials, Vol. 4,, (No. 2 ), 2012, p96 - 107
Sheridan, WS, Duffy, GP, Murphy, BP., Quantification of the Mechanical Properties of Customised Decellularized Porcine Carotid Artery for use as a Vascular Scaffold, The 17th Annual Conference of the Section of Bioengineering of the Royal Academy of Medicine in Ireland 2011, Galway, Ireland, 2011
Sheridan, WS, Duffy, GP, Murphy, BP., Customised Decellularized Vascular Scaffolds, World Conference on Regenerative Medicine 2011, Leipzig, Germany, 2011
Breen LT, McHugh PE, Murphy BP, HUVEC ICAM-1 and VCAM-1 synthesis in response to potentially athero-prone and athero-protective mechanical and nicotine chemical stimuli., Annals of biomedical engineering, 38, (5), 2010, p1880-92
Breen LT, McHugh PE, Murphy BP, Multi-axial mechanical stimulation of HUVECs demonstrates that combined loading is not equivalent to the superposition of individual wall shear stress and tensile hoop stress components., Journal of biomechanical engineering, 131, (8), 2009, p081001
Lenehan, B., Street, J., Murphy, B., Brennan, L., McHugh, P., Curtin, W., A biomechanical study comparing the compressive forces generated by a conventional 4.5 AO/ASIF cortical lag screw with a differentially pitched cortical compression screw, Acta of Bioengineering and Biomechanics, 11, (1), 2009, p31 - 35
MURPHY, Bruce; (IE). BLOWICK, Ray; (IE). BREEN, Liam T.; (IE)., NATIONAL UNIVERSITY OF IRELAND, GALWAY [IE/IE], Intravascular Treatment Device Field of the Invention, 2009, PCT/EP2009/062919
Murphy BP, Cuddy H, Harewood FJ, Connolley T, McHugh PE, The influence of grain size on the ductility of micro-scale stainless steel stent struts., Journal of materials science. Materials in medicine, 17, (1), 2006, p1-6
Breen, LT, McHugh, PE, McCormack, BA, Muir, G, Quinlan, NJ, Heraty, KB, Murphy, BP, Development of a novel bioreactor to apply shear stress and tensile strain simultaneously to cell monolayers, REVIEW OF SCIENTIFIC INSTRUMENTS, 77, 2006
McGarry, J.P., Murphy, B.P., McHugh, P.E., Prediction of changes in cell-substrate contact under cyclic substrate deformation using cohesive zone modelling, Mechanics of Biological Tissue, 2006, p177-187
McGarry, JP, Murphy, BP, McHugh, PE, Computational mechanics modelling of cell-substrate contact during cyclic substrate deformation, JOURNAL OF THE MECHANICS AND PHYSICS OF SOLIDS, 53, 2005
Breen, L.T., Murphy, B.P., McHugh, P.E., The development of a unique test RIG to simultaneously apply pulsatile and reversible shear and tensile forces to a monolayer of endothelial cells, Proceedings of the 2005 Summer Bioengineering Conference, 2005, 2005, p1372-1373
Savage P, O'Donnell BP, McHugh PE, Murphy BP, Quinn DF, Coronary stent strut size dependent stress-strain response investigated using micromechanical finite element models., Annals of biomedical engineering, 32, (2), 2004, p202-11
Stenson-Cox, C., Barron, V., Murphy, B.P., McHugh, P.E., Smith, T., Profiling the shear stress of atherosclerosis; a genomic view, Current Genomics, 5, (4), 2004, p287 - 297
Murphy BP, Prendergast PJ, Multi-axial fatigue failure of orthopedic bone cement - experiments with tubular specimens., Journal of materials science. Materials in medicine, 14, (10), 2003, p857-61
Kingston, R., Noël, J., Murphy, B., Lee, T.C., Walsh, M.G., Effects of Dall-Miles cables on the cement mantle in total hip arthroplasty: A cadaveric study, Hip International, 13, (1), 2003, p29 - 31
Stolk, J, Verdonschot, N, Murphy, BP, Prendergast, PJ, Huiskes, R, Finite element simulation of anisotropic damage accumulation and creep in acrylic bone cement, Engineering Fracture Mechanics, 71, 2003, p513-528
Murphy BP, Savage P, McHugh PE, Quinn DF, The stress-strain behavior of coronary stent struts is size dependent., Annals of biomedical engineering, 31, (6), 2003, p686-91
Murphy, BP, Prendergast, PJ, The relationship between stress, porosity, and nonlinear damage accumulation in acrylic bone cement, Journal of Biomedical Materials Research, 59, 2002, p646-654
Prendergast, P.J., Murphy, B.P., Taylor, D., Cristofolini, L., Minari, C., Viceconti, M., Discarding specimens for fatigue testing of orthopaedic bone cement: A comment on cristofolini et al. (2000) Fatigue Fract. Engng. Mater. Struct. 23, 953-957 (multiple letters), Fatigue and Fracture of Engineering Materials and Structures, 25, (3), 2002, p315-318
Murphy BP, Prendergast PJ, On the magnitude and variability of the fatigue strength of acrylic bone cement, International Journal of Fatigue , 22, 2000, p855 - 864
Murphy, BP, Prendergast, PJ, Measurement of non-linear microcrack accumulation rates in polymethylmethacrylate bone cement under cyclic loading, Journal of Materials Science-Materials in Medicine, 10, 1999, p779-781
Non-Peer-Reviewed Publications
Bruce Murphy, Stephen Johnson Barker, Gareth Gallagher, Cristina Purtill, 'A delivery system and method for delivery of an implant to a body lumen', EP24162460, 2024, 13 August 2024, The Provost, Fellows, Scholars and other Members of Board of Trinity College Dublin
Bruce Murphy, Brian Hughes, Alison Whelan, 'A FIXATION DEVICE FOR IMPLANTATION', EP4374826A1;WO2024110578A1, 2022, 13 August 2024, THE PROVOST, FELLOWS, FOUNDATION SCHOLARS, AND THE OTHER MEMBERS OF BOARD OF THE COLLEGE OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABETH NEAR DUBLIN
Eimear O'Connor, Bruce Murphy, 'A FIXATION DEVICE FOR IMPLANTATION', CA3226545A1;EP4122425A1;EP4373437A1;WO2023001661A1, 2021, 13 August 2024, The Provost, Fellows, Foundation Scholars, and the other members of Board, of the College of the Holy & Undiv. Trinity of Queen Elizabeth near Dublin
Paul Heneghan, Bruce Murphy, Lucy O'Keeffe, Martin Quinn, Conor Quinn, 'A HEART VALVE THERAPEUTIC DEVICE', XXXXXX, 2018, 13 August 2024, Trinity College Dublin
Aiden Flanagan, Conor Greaney, Bruce Murphy, Eimear Dolan, 'Injection Catheter', US2018085555A1, 2016, 13 August 2024, Boston Scientific
Conor Harkin, Garrett Ryan, Bruce Murphy, James Redmond, 'An implantable biocompatible expander suitable for treatment of constrictions of body lumen', XXXXX, 2015, 13 August 2024, Trinity College Dublin
Garrett Ryan, Liam Breen, Bruce Murphy, 'A TREATMENT DEVICE FOR INTERNALLY TREATING A VESSEL WITHIN A BODY', WO2015010963A1, 2013, 12 August 2024, PROVOST FELLOWS & SCHOLARS COLLEGE OF THE HOLY UNDIVIDED TRINITY OF QUEEN ELIZABETH NEAR DUBLIN
Bruce Murphy, James Crowley, Liam Breen, Michael Early, 'Implant Device', EP2478868A1;US2014031928A1;WO2012101190A1, 2011, 12 August 2024, PROVOST FELLOWS & SCHOLARS COLLEGE OF THE HOLY UNDIVIDED TRINITY OF QUEEN ELIZABETH NEAR DUBLIN
Bruce Murphy, John Vard, 'Intravasculature devices and balloons for use therewith', EP2241284A1;EP2241284B1;EP2429447A1;US2012109179A1;WO2010119110A1, 2009, 12 August 2024, National University of Ireland, Galway. Trinity College Dublin
Ray Blowick, Bruce Philip Murphy, 'Intravascular Treatment Device', EP2172242A1;EP2331188A1;JP2012504441A;US2011238154A1;WO2010037870A, 2008, 12 August 2024, National University Ireland, Galway
William Stephen Sheridan, BRUCE PHILIP Murphy, Peter McHugh, John Vard, 'A Catheter based Medical Device and Method for Delivery of a Therapeutic Agent', EP2065069A1;JP2011504778A;WO2009068573A1, 2007, 12 August 2024, National University of Ireland, Galway
Bruce Philip Murphy, Vincent Lawlor, 'Minimally Invasive Intravascular Treatment Device', CN101932282A;EP2200522A2;JP2010537680A;US2008077165A1;WO2009027531A2;WO2009027531A3, 2006, 12 August 2024, National University of Ireland, Galway
MURPHY BRUCE]; CROWLEY JAMES; BREEN LIAM; EARLY MICHAEL , 'Implant device', United States Patent Office, 8 October 2013, National University of Ireland, Galway
Research Expertise
Description
I am an expert in the process of innovating medical technologies. My research focus is the development of novel medical technologies to address validated clinical needs. In this process I build, lead, manage, and mentor teams to develop commercially viable excellent engineering solutions. For example, my lab has translated a heart valve concept from understanding the clinical need, to a solution that formed the key asset in a TCD spin-out. Croívalve has raised over $40M, employs over 30 staff members, and has performed first in human implants, which have demonstrated transformative improvements in symptoms for patients. Another example of my translational research relates to the clinical need of alleviating the symptoms of benign prostate hyperplasia. My lab developed the core technology/IP that formed the technical assets of the TCD spin-out. Proverum has gone on to raise over $55M, employs 30 employees and has finished enrolling patients into a prospective, multi-centre, sham controlled randomised study to evaluate the safety and effectiveness of the technology developed in my lab. To date, five medical device spin outs were established from research in my lab and I have successfully licensed two technologies. The companies employ over 120 employees and have raised over $150M in capital, the technologies have benefitted over 200 patients to date. My solutions have enhanced quality of life, prolonged life, and enhanced patient outcomes. In summary, my philosophy to Biomedical Engineering is that I believe I have a duty to use my substantial medical device engineering knowledge to improve patient outcomes, which I have done to date and continue to do with novel solutions to address clinical needs. Because of my work TCD has become an internationally renowned university in the field of medical device innovation, TCD recognised this by awarding me the Provost's Innovation Award in 2023.Projects
- Title
- The Development of a Transcatheter Tricuspid Valve Repair System (CroiValve)
- Summary
- Bruce Murphy and consultant cardiologist Martin Quinn have devised an easy-to-use minimally invasive solution for treating patients with greater than moderate tricuspid regurgitation. This is a significant clinical need with up to 1.6m patients in the US eligible for this therapy. The tricuspid valve is often termed the forgotten heart valve, as surgical interventions are carried out on less than 1% (8,000) of the estimated 1.6m eligible patient population in the US. This is because patients with tricuspid valve disease often have significant co-morbidities and many patients are not candidates for surgery. Even in those who are fit for surgery the risks are high with an operative mortality of between 10% and 35%. Thus there is a significant clinical need for a minimally invasive solution. The technology that we propose to develop uses standard procedures and techniques that are used during pacemaker lead implantation. This approach will ensure safety, ease of use and a high physician adoption rate. The underlying technology relies on the development of an implant that can always be placed in the correct position to inhibit regurgitation of the tricuspid valve. The technology is currently the subject of an Irish patent filing (priority date Sep 2014) and a subsequent PCT filing in Sep 2015. The competitive landscape is reasonably limited. The Cleveland Clinic, Cardio Solutions and Edwards Lifesciences have initiated R&D programs that utilise a similar approach to the one proposed in this application. Galway based 4Tech have a unique solution. While the Mitralign system is a translation of their mitral system to the tricuspid position - this system has many intricacies and may have a low user adoption rate. In summary, the competitive products do not posses the desired user requirements of ease-of-use, adjustability and atraumatic properties that we are proposing. A considerable market opportunity exists in this field, for example: By 2020 there will be approximately 56 million US citizens over the age of 65, utilising a conservative figure of 1.5% of this population experiencing greater than moderate TR (estimated from the Framingham study) equates to 850,000 patients with greater than moderate TR. The cohort of this patient-set that could benefit immediately from treatment due to severe quality of life interfering disease can be determined from De Meester et al, whereby they observed that 10% of patients undergoing a diagnostic procedure had significant TR. Implying that 85,000 patients in the US would have immediate quality of life benefits from a tricuspid intervention. An estimated total US market of $1.7Bn exists. Potentially the OUS market would be another $1.7Bn, equating to a global market opportunity of approximately $3.4Bn. The overall objective of this proposal is to develop the CroiValve technology to the value add point that it has been verified in in vivo medium-term pre-clinical studies. Furthermore a robust regulatory, clinical, technical and business plan will be developed in parallel to assembling a rounded team to raise future finance and develop the device through a European regulatory submission and investigational device trials in Europe.
- Funding Agency
- Enterprise Ireland
- Date From
- 1 Oct 2016
- Date To
- 31 July 2018
- Title
- CTO Re-entry Device Design & Development
- Summary
- This collaborative research project will focus on the design and development of a re-entry device for the treatment of chronic total occlusions due to peripheral arterial disease (PAD). Currently, the company uses glass and/or silicone models to iterate designs at an early concept stage and this helps to evaluate product performance and product deliverability to the site of the CTO. However, the proposed solution for this project will be dependent on its ability to exit the vessel wall after crossing a CTO in the sub-intimal (SI) space. This is a very delicate procedure which requires both dexterity and finesses by the end-user and will require a novel solution to achieve this technically challenging endpoint. As a result, both the penetration capability and the trackability of the device will have to be developed using more clinically relevant models earlier in the NPD lifecycle. Utilising Prof. Murphy research group's expertise, particularly their capability to successfully penetrate the vessel wall and track though the SI space and their extensive knowledge of the mechanical characterization of vascular tissue will provide the Clearstream with the additional capability they require to develop a next generation CTO device.
- Funding Agency
- Enterprise Ireland
- Date From
- Dec 2015
- Date To
- Nov 2017
- Title
- AMCARE - ADVANCED MATERIALS FOR CARDIAC REGENERATION
- Summary
- AMCARE develops regenerative therapies which aim to circumvent some of the limitations of current treatments for MI patients. Our rationale is to use biomaterials to deliver cells or growth factors to the heart.Biomaterials are materials in which cells can be encapsulated or attached, can support delivered cell growth and which are tolerated by the body. In this way, delivered therapeutics are retained within the heart tissue for extended periods. In addition, biomaterials provide a protective environment for delivered stem cells and enhance stem cell survival in the harsh conditions of the infarct. By combining regenerative stem cells and growth factors within the same biomaterial, our aim is to maximise regeneration in the heart thanks to the synergistic effects of both therapeutics.
- Funding Agency
- European Commission
- Date From
- Dec 2014
- Date To
- Nov 2018
- Title
- Westland mitral valve
- Summary
- We have developed a minimally invasive mitral valve replacement device on a previous Enterprise Ireland commercialization fund. We have continued the development work on this medical device post the Enterprise Ireland funding to assess its safety and efficacy. The device's key attributes lie in the technical features that allow for safe and simple fixation of the prosthesis to the native mitral valve anatomy. The device is currently being tested in large animals and we are open to pursuing licensing agreements with structural heart medical device companies.
- Date To
- Dec 2017
- Title
- The in vivo evaluation of an easy to position transcatheter mitral valve repair/replacement device
- Summary
- A ssignificant number of individuals in the developed world suffer from moderate to severe mitral valve disease, however 50-80% of the patients that present themselves at surgical centres are denied surgery due to the high risk of intraoperative death. One of the reasons for a high death rate is the trauma that is associated with open heart surgery. There is a clinical need to treat these patients with a less traumatic minimally invasive technology that will result in minimal post procedure mortality. To meet this need over the last 10 years there has been a drive to develop transcatheter technologies that are capable of repairing the mitral valve of these patients in a minimally invasive manner. These technologies have advanced mainly in two technology branches: (1) leaflet plication and (2) coronary sinus annuloplasty. However these two technologies have a number of drawbacks. Our "gap" or "angle" is that a safe effective technology that is low in profile and easy to deliver will be accepted by cardiologists and heart surgeons as the preferred device due to its user-friendliness. We are developing one of the most straightforward and easy to use devices in the arena of transcatheter mitral valve repair/replacement.
- Funding Agency
- Enterprise Ireland
- Date From
- July 2011
- Date To
- Aug 2013
- Title
- CardioColl - a collagen-alginate composite scaffold to enhance the cardiac stem cell response and promote healing in heart failure
- Summary
- This project is investigating the hypothesis that cardiac stem cells can repair damaged myocardium, once the correct biochemical signals can be delivered to the site of the damaged heart muscle.
- Funding Agency
- Enterprise Ireland
- Date From
- 16/01/2012
- Date To
- 15/01/2013
- Title
- Evaluating the safety and efficacy and commercial case for a new Chemical Renal DenervatioN (C-RDN) catheter
- Summary
- We are proposing to develop a new C-RDN catheter within the space of intravascular management of hypertension. The current leading CE approved technology in this space is the Medtronic/Ardian catheter. This device operates in the Thermal RDN (T-RDN) arena. Recent clinical trials of this device have proven the principal that renal denervation can reduce high blood pressure in patients with resistant hypertension. This catheter burns the nerve fibers that surround the renal arteries and disrupts the sympathetic nervous system, and the subsequent effect for the patient is a reduction in blood pressure. This result has been described as "remarkable" and opens up a new medical device market estimated to be in the region of $25-30Bn. Medtronic purchased Ardian for $800m in 2010 to achieve first to market in the T-RDN field, returning over 10 times the invested capital to the investors. Subsequent to these recent clinical trial results a number of "fast followers" are developing catheters in the T-RDN space. However, T-RDN has a number of major disadvantages: (i) Patients are in severe pain during the procedure. (ii) Collateral damage is caused within the arterial wall, this is in the form of burning the media of the renal artery. Potentially this collateral damage may cause future stenoses or aneurysm formation. To overcome these disadvantages we are proposing to develop a controlled C-RDN catheter.
- Funding Agency
- Enterprise Ireland
- Date From
- July 2012
- Date To
- Nov 2013
- Title
- Development of a custom decellularized vascualr graft.
- Summary
- 1.0 Introduction and objectives Numerous research groups have endeavoured to tissue engineer functional small diameter (<5mm) vascular grafts in an in vitro environment (see (Naito et al., 2011, L'Heureux et al., 2007, Daly et al., 2005, Mitchell and Niklason, 2003) for review articles in the field). However, to date, no research group has achieved the goal of producing a regulatory approved tissue engineered medical device during the 25 year period that the research field has been active. Considerable progress has been realized, and current research is incrementally progressing towards the ultimate goal. However, there is still considerable scope available to investigate novel methods that may achieve the goal of producing a safe and effective clinical product. Moreover, if this goal is achieved the end product has a secondary function - as a laboratory tool. This tool has the potential to be used to investigate the pathology of atherosclerosis and enable the development of new therapies to treat atherosclerosis and restenosis. To this end, we are proposing to develop a novel tissue engineered vascular graft utilising new methodologies for repopulating customised decellularized arterial segments. If successful, this tissue engineered arterial segment may lead to a new bypass graft therapy for small diameter blood vessels, or a standard laboratory tool that could be used to investigate the pathology and treatment of vascular disease. To advance the knowledge in the field towards the goal of achieving a new solution for revascularisation our research proposal aims to answer five specific questions: 1. Can decellularized porcine arterial tissue be modified to produce a scaffold with sufficient strength that will permit rapid smooth muscle cell (SMC) and endothelial cell (EC) repopulation? 2. What is the optimum cell source for repopulating our custom decellularized scaffold? 3. Can we achieve a stable/quiescent SMC populated media by determining the most favourable mechanical stimuli? 4. Will an in vivo model verify the approach? i. Utilising our optimised stable repopulated scaffold ii. Utilising our optimised cell-free scaffold 5. Can we successfully engineer a laboratory model that mimics in vivo restenosis?
- Funding Agency
- College award
- Date From
- Sep 2012
- Date To
- Sep 2013